Century Therapeutics (IPSC) Common Equity (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Common Equity data on file, last reported at $264.7 million in Q1 2026.

• Common Equity for Q1 2026 came in at $264.7 million, up 10.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $264.7 million (up 10.11% YoY), and the FY2025 annual result was $158.9 million, down 1.5% from the prior year.
• Common Equity rose to $264.7 million in Q1 2026 per IPSC's latest filing, from $158.9 million in the prior quarter.
• Over five years, Common Equity peaked at $386.7 million in Q1 2022 and troughed at $158.9 million in Q4 2025.
• A 5-year average of $242.0 million and a median of $222.1 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity soared 522.32% in 2022, then sank 38.97% in 2023.
• A 5-year view of Common Equity shows it stood at $302.7 million in 2022, then slumped by 38.97% to $184.8 million in 2023, then dropped by 12.66% to $161.4 million in 2024, then retreated by 1.5% to $158.9 million in 2025, then jumped by 66.57% to $264.7 million in 2026.
• Business Quant data shows IPSC's Common Equity at $264.7 million in Q1 2026, $158.9 million in Q4 2025, and $176.3 million in Q3 2025.